Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Dystrophic Epidermolysis Bullosa Clinical Trial

Official title:

A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy, and Systemic Exposure in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa (DDEB / RDEB) Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05529134
• Other study ID #: PTW-002-001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: April 30, 2023
• Est. completion date: July 31, 2024

Study information

• Verified date: March 2023
• Source: Phoenicis Therapeutics
• Contact: Ramsey Johnson
• Phone: 978-726-1478
• Email: ramsey[@]phoenicistx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A double-blind, randomized, intra-patient placebo- controlled, multiple dose study of PTW-002 evaluating safety, proof of mechanism, preliminary efficacy, and systemic exposure in patients with Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene. Up to two RDEB patients 4 to 17 years of age and up to 6 DDEB patients 4 years of age and older will be enrolled.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 8
• Est. completion date: July 31, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

1. Patients, and/or their legal guardian(s), if the patient is under the legal age of consent, must provide written Informed Consent or Assent, in accordance with national and/or local laws, prior to the conduct of any study related procedures. In addition, if applicable, a minor child must provide informed Assent in accordance with national and/or local laws and in compliance with the recommendations of the approving Institutional Review Board.

2. Male or female, = 4 - 17 years of age at Screening for RDEB patients, and = 4 years of age at Screening for DDEB patients.

3. Have a confirmed diagnosis of RDEB or DDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene. Historical genetic data may be acceptable with Medical Monitor approval.

4. Have at least one TWA that shows no signs of local infection, and contains a target lesion that is either new or has shown dynamic healing in the past and complies with the following additional criteria:

1. surface area of the target lesion ranging from 5 to 30 cm2, located centrally in the selected TWA.

2. exposed sub-epidermal tissue to allow absorption of the investigational medicinal product (IMP).

3. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.

5. Have a caregiver or support person available, who can follow study instructions in compliance with the protocol and attend study site visits with the patient as required, in the opinion of the Investigator.

6. Female patients who have reached menarche and male patients must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, effective methods of contraception for up to 3 months following their last dose of IMP.

Exclusion Criteria:

1. Pregnant or breast-feeding female.

2. Hemoglobin level at Screening requiring transfusion. The patient may be rescreened when the condition is considered stable.

3. Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5 half-lives, whichever is longer, prior to Baseline visit.

4. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma.

5. Life expectancy less than 6 months, as assessed by the Investigator.

6. Current or known history of clinically significant hepatic or renal disease that in the opinion of the Investigator, could impact patient safety or study participation.

7. Bleeding disorder or condition, requiring the use of anticoagulants to be confirmed by activated partial thromboplastin time (aPTT) by local lab within 48 hours of first treatment.

8. Use of any investigational drug or device within 28 days or 5 half-lives of the Baseline visit, whichever is longer, or plans to participate in another study of a drug or device during the study period. The washout of 5 half-lives does not apply to gene and cell therapy.

9. History of cell therapy requiring treatment with exclusionary medication.

10. History of skin-based gene therapy to the TWA.

Related Conditions & MeSH terms

• Dystrophic Epidermolysis Bullosa
• Epidermolysis Bullosa
• Epidermolysis Bullosa Dystrophica

Intervention

Drug:
• PTW-002 10 mg/g gel
poloxamer hydrogel for topical administration
• Placebo
placebo poloxamer hydrogel for topical administration

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital	Cincinnati	Ohio
United States	Stanford Health Care	Stanford	California
United States	UMass Memorial Medical Center	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Phoenicis Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events (AEs)/serious adverse events (SAEs)		Baseline through Week 32
Primary	Assessment of exon 73 exclusion in COL7A1 mRNA, measured by droplet digital polymerase chain reaction (ddPCR)		Week 4
Secondary	Change in uptake of PTW-002 by cells at the basement membrane by fluorescent in situ hybridization (FISH) analysis		Week 4
Secondary	Effect of PTW-002 on wound healing by change in wound size (surface area)		Baseline through Week 16
Secondary	Effect of PTW-002 on skin strength by onset of (re)blistering of a healed wound		Baseline through Week 16
Secondary	Systemic exposure through serum levels of PTW-002 after topical administration to the target wound area (TWA)		Baseline through Week 32
Secondary	Effect of PTW-002 on the presence of collagen type VII protein measured by immunofluorescent staining		Week 8
Secondary	Effect of PTW-002 on the presence of anchoring fibrils measured by electron microscopy		Week 8